Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open Label Adaptive Ascending Multiple-Dose Study of BMS-986004 in Immune Thrombocytopenia
2014-001429-33Phase 2Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Oct 2014
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of letolizumab in immune thrombocytopenia (ITP), sponsored by Bristol Myers Squibb. Primary endpoint: Safety and tolerability. Started Oct 2014; status: completed.
02
Drugs
letolizumab
03
Conditions
immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on 2014-001429-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-001429-33.